TWi Announces ANDA Approval of Generic Procardia XL® Tablets 30 mg, 60 mg and 90mg in the United States

TAIPEI, TAIWAN--April 7, 2014-- TWi Pharmaceuticals, Inc., today announces the ANDA approval of the generic equivalent to Procardia XL® (Nifedipine) Extended Release Tablets, 30 mg, 60 mg and 90mg, in the United States. TWi has begun the launch preparation with its US distributor partner and will begin marketing the product as soon as the launch preparation is completed.

Procardia XL® 30 mg, 60mg and 90 mg, Extended Release Tablets marketed by Pfizer Inc and the generic equivalent pharmaceuticals marketed by other companies, had annual combined sales of approximately $116 million in the United States, according to IMS data as of December 2013.


About TWi Pharmaceuticals, Inc.


TWi Pharmaceuticals, Inc. is a leading specialty pharmaceutical company based in Taipei, Taiwan, focusing on the development of high barrier generic prescription products ranging from oral controlled release dosage form to novel drug delivery systems including the utilization of nanoparticles, transdermal, and polymeric oral delivery systems. Leveraging its internal research and development capabilities, together with operational flexibility, process development, manufacturing and regulatory expertise, TWi Pharmaceuticals concentrates on products and technologies that present significant barriers to entry or offer Paragraph IV first-to-file or first-to-market opportunities in the United States. For more information of TWi Pharmaceuticals, please visit www.twipharma.com.


Liru Yeh
Head of Investor Relations
Tel: +886-2-2657-3350
email: liru.yeh@twipharma.com